{"id":7838,"date":"2024-09-11T06:00:00","date_gmt":"2024-09-11T06:00:00","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-informs-of-exercise-price-for-the-warrants-of-series-to-3-3\/"},"modified":"2024-11-18T19:04:31","modified_gmt":"2024-11-18T19:04:31","slug":"acarix-informs-of-exercise-price-for-the-warrants-of-series-to-3-3","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-informs-of-exercise-price-for-the-warrants-of-series-to-3-3\/","title":{"rendered":"Acarix informs of exercise price for the warrants of series TO 3"},"content":{"rendered":"
\n

Acarix AB (“Acarix” or the “Company”), a leader in rapid AI and acoustics-based cardiac diagnostics, announces that the exercise price of warrants of series TO 3 (the “Warrants”) has been set to SEK 0.25 per new share meaning Acarix can receive a maximum of SEK 22.6 million through the exercise of the Warrants. The exercise period commences today, September 11, 2024, and will run to and including Wednesday, September 25, 2024. A letter from the CEO has been published on the Company website, www.acarix.com. The exercise period commences today, September 11, 2024, and will run to and including Wednesday, September 25, 2024. The exercise price for the Warrants has been calculated as 70 percent of the volume-weighted average price (“VWAP”) during the measurement period August 23 – September 6, 2024, but no less than SEK 0.25 and no more than SEK 0.50. Each warrant entitles to subscription of one (1) new share in Acarix and the exercise price of warrants of series TO 3 (the “Warrants”) has now been set to SEK 0.25 per new share. Thus, Acarix can receive a maximum of SEK 22.6 million through the exercise of Warrants. Acarix has previously announced that the Warrants are fully secured through declarations of intents and guarantee agreements.<\/strong><\/p>\n<\/div>\n

\n

A letter from the CEO and complete terms and conditions for the Warrants are available on the Company’s website (www.acarix.com<\/a>) and in the prospectus prepared by the Board of Directors of Acarix in connection with the Rights Issue. The prospectus is available on the Company’s website. It is also available on the Swedish Financial Supervisory Authority’s website www.fi.se<\/a>.<\/p>\n

Exercise of warrants<\/strong>
Trustee-registered Warrants<\/em>
If the warrant holder has their Warrants in a share depository, in an investment savings account (Sw. ISK<\/em>), or an endowment insurance (Sw. Kapitalförsäkring<\/em>) (trustee-registered holdings), subscription and payment will take place with the nominee, who will provide further instructions on the procedure for exercising the Warrants. Warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.<\/p>\n

Directly registered Warrants (VP account)<\/em>
Application is made via a subscription form that will be available on Carnegie Investment Bank AB (publ)’s website www.carnegie.se<\/a> and Acarix’s website www.acarix.com<\/a>. A pre-printed subscription form will be sent to directly registered warrant holders. Payment is made according to instructions on the application form. Both the subscription form and payment must be received by Carnegie Investment Bank AB (publ) by September 25, 2024.<\/p>\n

IMPORTANT INFORMATION<\/strong>
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Acarix in any jurisdiction, neither from Acarix nor from someone else.<\/p>\n

This press release is not a prospectus for the purposes of Regulation (EU) 2017\/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction.<\/p>\n

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. <\/p>\n

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix informs of exercise price for the warrants of series TO 3<\/a><\/p>\n<\/div>\n